Last updated: February 20, 2026
QVAR REDIHALER is marketed by Teva Pharmaceutical Industries Ltd. as an inhaled corticosteroid for asthma management. It is a brand-name product in the US, with key manufacturing and supply chain components managed by Teva.
Authorized Manufacturer and Supply Chain
Primary Manufacturer:
- Teva Pharmaceutical Industries Ltd.: Produces and markets QVAR REDIHALER in the United States and other regions. It holds the final product approval from the FDA.
Contract Manufacturers:
- Teva collaborates with several contract manufacturing organizations (CMOs) globally for the production of various components, including active pharmaceutical ingredients (APIs) and inhaler devices. Specific CMO names are not publicly disclosed.
Component Suppliers:
- API Suppliers: Teva sources beclomethasone dipropionate, the active ingredient, from multiple suppliers. These are typically large-scale chemical manufacturers, potentially including companies like CEPSA (a Spanish chemical company) or other global raw material suppliers.
- Device Components: Inhaler device parts are manufactured by specialized component suppliers, often involving injection molders for plastic parts and precision engineering firms for metering valves.
Supply Security and Market Dynamics
- Capabilities for QVAR REDIHALER are concentrated within Teva's production facilities, providing control over quality and supply.
- Teva has reported manufacturing capacities sufficient to meet global demand, although the COVID-19 pandemic disrupted global supply chains, impacting availability at times.
- The product's exclusivity is protected through patents, which could influence sourcing and the entry of generic competitors.
Global Supply Considerations
- QVAR REDIHALER is primarily sold in the US market. Outside the US, Teva markets a different formulation, QVAR Metered Dose Inhaler (MDI).
- No known third-party suppliers or secondary manufacturing sources are publicly recognized for QVAR REDIHALER in the US market.
Key Suppliers Summary Table
| Component |
Supplier Type |
Known or Suspected Sources |
Notes |
| Active Pharmaceutical Ingredient (API) |
Chemical manufacturers |
CEPSA, others |
API supply mostly via contract manufacturers |
| Inhaler device components |
Precision manufacturing firms |
Undisclosed |
Plastic parts, valves, assembly |
| Final assembly and packaging |
Teva facilities |
Teva-controlled |
Regulatory compliance licensing |
Market and Supply Risks
- Patent protections constrain generic proliferation, stabilizing supply and pricing for Teva.
- Supply chain disruptions (e.g., raw material shortages, geopolitical issues) can impact production volumes.
- Lack of disclosed secondary suppliers limits diversification options for downstream stakeholders.
Conclusion
Teva is the sole authorized producer of QVAR REDIHALER, with manufacturing tightly integrated within its global facilities and supported by undisclosed contract manufacturing partners. Raw material sourcing appears centralized with multiple chemical suppliers, but specific names are undisclosed. Market supply stability depends heavily on Teva’s manufacturing capacity and supply chain management.
Key Takeaways
- Teva is the sole manufacturer and marketer of QVAR REDIHALER.
- API is sourced from multiple unidentified chemical suppliers.
- The inhaler device is produced by specialized component manufacturers, but their identities remain proprietary.
- Supply chain resilience depends on internal capacity and Teva’s procurement practices.
- The product’s patent status shields it from generic competition, maintaining supply security.
FAQs
1. Are there alternative suppliers for QVAR REDIHALER?
No. Teva holds exclusive rights for manufacturing and distribution in major markets, with no known third-party or secondary suppliers.
2. Can future generic versions affect the supply of QVAR REDIHALER?
Yes. Patent expirations could allow generic competitors, potentially introducing alternate manufacturing sources, but none are available currently.
3. What risks could disrupt QVAR REDIHALER supply?
Raw material shortages, manufacturing capacity constraints, regulatory delays, or geopolitical issues affecting supply chain components.
4. How does Teva ensure quality in the supply chain?
By controlling manufacturing facilities and relying on certified contract manufacturing organizations with strict regulatory compliance.
5. Is there transparency about the API suppliers?
No. The specific chemical suppliers for beclomethasone dipropionate remain undisclosed.
References
- U.S. Food and Drug Administration. (2021). QVAR REDIHALER (beclomethasone dipropionate) Inhalation Aerosol, for Oral Inhalation. FDA. https://www.accessdata.fda.gov
- Teva Pharmaceutical Industries Ltd. (2022). Annual Report. Teva. https://www.tevapharm.com
- European Medicines Agency. (2022). QVAR (beclomethasone dipropionate): Summary of Product Characteristics. EMA. https://www.ema.europa.eu
